Pharmafile Logo

News and Press Releases

Awen Oncology secures significant new funds to advance pioneering cancer therapeutics

23 April 2026 -- Anglesey, UK -- Awen Oncology, a pioneering Wales-based therapeutics company developing next-generation cancer treatments, has secured funds from a number of sources, worth seven figures, which...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2026

Awen Oncology

Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026  

Nonclinical findings from pharmacology, pharmacokinetics, and toxicology studies support the advancement of SBE303 into clinical development with a favorable therapeutic index (TI), with its first-in-human Phase I clinical trial began...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 20, 2026

Samsung Bioepis
76, Songdogyoyuk-ro, Yeonsu-gu, Incheon

Integrated DNA Technologies Expands Coralville Manufacturing Footprint to Support Growing Global Demand for MRD Solutions

Expanded footprint delivers speed, scale and customization minimal residual disease (MRD) innovators need without compromising quality Increased production capacity leverages IDT’s highly specialized, high-throughput manufacturing platform. 20 April 2026 --...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: April 20, 2026

Integrated DNA Technologies (IDT)
custcare@idtdna.com

Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy

Agreement will enable selection of Kahimmune’s first companion neoantigen therapy candidate against colorectal cancer and pancreatic cancer, with financial support from Bpifrance   Kahimmune exploits dark genome to develop next-generation...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 18, 2026

Kahimmune Therapeutics
contact@kahimmune.com
2 Avenue Du Blanchissage, 84000 Avignon, France

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026 

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2026

Asgard Therapeutics
info@asgardthx.com
Medicon Village, 223 81 Lund, Sweden

STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation 16 April...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2026

Storm Therapeutics
info@stormtherapeutics.com
Babraham Hall House, Babraham, Cambridge CB22 3AT

Oncodesign Services extends collaboration with GIP ARRONAX to strengthen astatine-211 supply for targeted alpha radiotherapy

13 April 2026 -- Dijon, France -- Oncodesign Services has extended its collaboration with GIP ARRONAX to secure access to astatine-211 (At-211) as well as other radionuclides used in targeted...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 13, 2026

Oncodesign Services
contact@oncodesign-services.com
20 Rue Jean Mazen 21 000 Dijon France

Touchlight Partners with SVF Vaccines to Advance Innovative Hepatitis B/D Vaccine to Clinic

9 April 2026 -- London, UK -- Touchlight, a leading biotechnology company specialising in cell-free DNA manufacturing, is proud to announce a strategic partnership with SVF Vaccines to progress SVF’s innovative...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 9, 2026

Touchlight
info@touchlight.com
Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

First patient dosed in France, expanding the DOMISOL study beyond Australia DT 7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program. 9...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 9, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

Symeres and Ambagon Therapeutics collaborate on molecular glue research in colorectal cancer

31 March 2026 -- Nijmegen, Netherlands -- Symeres, a leading CRDMO for drug discovery and development has partnered with Ambagon Therapeutics, a pre-clinical biotechnology company, to explore a new class...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 31, 2026

Johnson & Johnson’s DARZALEX (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma Milestone is a testament to ten years of daratumumab experience and innovation, continuing...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: March 27, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

BioCurie to Receive Up to $9.3 Million ARPA-H Award to Build AI Platform for Scalable Gene Therapy Manufacturing

12 March 2026 -- Delaware and Massachuetts, US -- BioCurie, a TechBio company building an AI-driven digital platform for cell and gene therapy manufacturing, was awarded up to $9.3 million...

Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: March 12, 2026

BioCurie
contact@biocurie.com
112 South French Street Wilmington, Delaware 19801 USA

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance. 10 March...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics

Innovative glycobiology platform aimed at enhancing the efficacy, safety, and scalability of next-generation antibody therapeutics across multiple disease areas 9 March 2026 -- Paris, France -- kyron.bio, a biotechnology company pioneering...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

kyron.bio
hello@kyron.bio
Paris Biotech Santé-Site Cochin 27 rue du Faubourg Saint Jacques 75014 Paris, France

Medidata Expands Partnership with The Menarini Group, Deploying Medidata’s Study Build AI Technology to Accelerate Global Oncology Pipeline

Fourteen-year collaboration enters a new phase as Menarini evolves its use of the Medidata Platform, combining established clinical workflows with AI to power its global oncology pipeline 9 March 2026...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA